JP6991966B2 - Ｌｐａの遺伝子発現の阻害のための組成物及び方法 - Google Patents

Ｌｐａの遺伝子発現の阻害のための組成物及び方法 Download PDF

Info

Publication number
JP6991966B2
JP6991966B2 JP2018516738A JP2018516738A JP6991966B2 JP 6991966 B2 JP6991966 B2 JP 6991966B2 JP 2018516738 A JP2018516738 A JP 2018516738A JP 2018516738 A JP2018516738 A JP 2018516738A JP 6991966 B2 JP6991966 B2 JP 6991966B2
Authority
JP
Japan
Prior art keywords
rnai agent
seq
lpa
lpa rnai
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018516738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529732A5 (OSRAM
JP2018529732A (ja
Inventor
ステイシー メルクイスト，
スティーブン カナー，
デイビッド ビー． ロゼマ，
デイビッド エル． ルイス，
ローレン ジェイ． アルメイダ，
ダレン エイチ． ウェイクフィールド，
ウラジーミル エス． トルベツコイ，
タオ ペイ，
ゼン リ，
アーロン アルメイダ，
Original Assignee
アローヘッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アローヘッド ファーマシューティカルズ インコーポレイテッド filed Critical アローヘッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2018529732A publication Critical patent/JP2018529732A/ja
Publication of JP2018529732A5 publication Critical patent/JP2018529732A5/ja
Application granted granted Critical
Publication of JP6991966B2 publication Critical patent/JP6991966B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018516738A 2015-10-01 2016-09-30 Ｌｐａの遺伝子発現の阻害のための組成物及び方法 Active JP6991966B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US62/235,816 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US62/346,304 2016-06-06
US201662383221P 2016-09-02 2016-09-02
US62/383,221 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039949A Division JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018529732A JP2018529732A (ja) 2018-10-11
JP2018529732A5 JP2018529732A5 (OSRAM) 2019-11-07
JP6991966B2 true JP6991966B2 (ja) 2022-02-03

Family

ID=58424351

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018516738A Active JP6991966B2 (ja) 2015-10-01 2016-09-30 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2021039949A Active JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2022096415A Active JP7442574B2 (ja) 2015-10-01 2022-06-15 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2023199857A Withdrawn JP2024009262A (ja) 2015-10-01 2023-11-27 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021039949A Active JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2022096415A Active JP7442574B2 (ja) 2015-10-01 2022-06-15 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2023199857A Withdrawn JP2024009262A (ja) 2015-10-01 2023-11-27 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Country Status (37)

Country Link
US (4) US9932586B2 (OSRAM)
EP (2) EP4029941A1 (OSRAM)
JP (4) JP6991966B2 (OSRAM)
KR (2) KR102728481B1 (OSRAM)
CN (1) CN108368506A (OSRAM)
AU (3) AU2016331084B2 (OSRAM)
BR (1) BR112018006489A2 (OSRAM)
CA (1) CA3000397A1 (OSRAM)
CL (1) CL2018000803A1 (OSRAM)
CO (1) CO2018003678A2 (OSRAM)
CR (1) CR20180231A (OSRAM)
CY (1) CY1125263T1 (OSRAM)
DK (1) DK3356529T3 (OSRAM)
EA (1) EA038478B1 (OSRAM)
ES (1) ES2896298T3 (OSRAM)
HR (1) HRP20211410T1 (OSRAM)
HU (1) HUE055942T2 (OSRAM)
IL (3) IL300438A (OSRAM)
JO (2) JOP20210043A1 (OSRAM)
LT (1) LT3356529T (OSRAM)
MA (1) MA43347B1 (OSRAM)
MX (2) MX2018003833A (OSRAM)
MY (1) MY195796A (OSRAM)
PE (1) PE20181139A1 (OSRAM)
PH (1) PH12018500713A1 (OSRAM)
PL (1) PL3356529T3 (OSRAM)
PT (1) PT3356529T (OSRAM)
RS (1) RS62523B1 (OSRAM)
SG (1) SG10202008530TA (OSRAM)
SI (1) SI3356529T1 (OSRAM)
SM (1) SMT202100622T1 (OSRAM)
TN (1) TN2018000094A1 (OSRAM)
TW (3) TWI784934B (OSRAM)
UA (1) UA121998C2 (OSRAM)
UY (1) UY36926A (OSRAM)
WO (1) WO2017059223A2 (OSRAM)
ZA (1) ZA202106265B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
NZ744357A (en) * 2016-03-07 2025-09-26 Arrowhead Pharmaceuticals Inc Targeting ligands for therapeutic compounds
KR102856522B1 (ko) 2016-09-02 2025-09-08 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
CN110520531A (zh) * 2017-04-05 2019-11-29 赛伦斯治疗有限责任公司 产品和组合物
JP2020526192A (ja) * 2017-07-06 2020-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法
US10597657B2 (en) * 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
WO2019055633A1 (en) * 2017-09-14 2019-03-21 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS AND COMPOSITIONS FOR INHIBITING ANALOGUE EXPRESSION OF ANGIOPOIETIN 3 (ANGPTL3) AND METHODS OF USE
MX2020003596A (es) 2017-10-04 2020-07-22 Avidity Biosciences Inc Composiciones de acido nucleico-polipeptido y usos de las mismos.
EP3697909A4 (en) * 2017-10-17 2021-10-13 Arrowhead Pharmaceuticals, Inc. RNAI-BASED AGENTS AND COMPOSITIONS INTENDED TO INHIBIT ASIALOGLYCOPROTEIN RECEPTOR 1 EXPRESSION
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
FI3710586T3 (fi) * 2017-11-13 2023-03-02 Nukleiinihappoja LPA:n ekspression inhiboimiseksi solussa
WO2020061177A1 (en) * 2018-09-19 2020-03-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
WO2020099476A1 (en) * 2018-11-13 2020-05-22 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
CA3142283A1 (en) * 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US20220307024A1 (en) * 2019-06-17 2022-09-29 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
CN112442499A (zh) * 2019-08-30 2021-03-05 恩智（广州）医药科技有限公司 一种抑制MCM7的siRNA、组合物及其应用
MX2022007005A (es) 2019-12-09 2022-08-25 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de lpa.
EP4126967A1 (en) * 2020-03-23 2023-02-08 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
EP4192954A1 (en) * 2020-08-05 2023-06-14 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting lpa expression
WO2022079221A1 (en) * 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CA3199678A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
WO2023034719A1 (en) 2021-08-30 2023-03-09 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4402263A2 (en) 2021-09-14 2024-07-24 Argonaute Rna Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) * 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
EP4448540A1 (en) 2021-12-15 2024-10-23 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4450624A4 (en) * 2021-12-16 2025-03-26 Tuojie Biotech (Shanghai) Co., Ltd. LPA-TARGETTING SIRNA AND CONJUGATE
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024032681A1 (zh) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
KR20250131826A (ko) * 2023-01-13 2025-09-03 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
CN119384503A (zh) * 2023-04-03 2025-01-28 翰森（上海）健康科技有限公司 靶向LPA基因的RNAi剂及其用途
WO2024222686A1 (zh) * 2023-04-24 2024-10-31 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
CN120035578A (zh) 2023-05-19 2025-05-23 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
CN119343449A (zh) * 2023-05-24 2025-01-21 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024279456A1 (en) * 2023-05-31 2025-12-04 Arrowhead Pharmaceuticals, Inc. HEPATIC DELIVERY PLATFORMS FOR MULTIMERIC RNAi AGENT CONJUGATES AND METHODS OF USE THEREOF
TW202513798A (zh) * 2023-05-31 2025-04-01 大陸商上海拓界生物醫藥科技有限公司 一種靶向ＬＰＡ的ｄｓＲＮＡ及其應用
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (en) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
WO2025119212A1 (zh) * 2023-12-05 2025-06-12 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141703A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
WO2014179625A1 (en) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
JP2015522255A (ja) 2012-05-24 2015-08-06 アイシス ファーマシューティカルズ， インコーポレーテッド アポリポタンパク質（ａ）発現を調節するための方法および組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
ATE408699T1 (de) 1999-03-10 2008-10-15 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US8513207B2 (en) 2008-12-18 2013-08-20 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
NZ601737A (en) 2010-02-24 2013-06-28 Arrowhead Res Corp Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130136494A (ko) 2010-12-29 2013-12-12 애로우헤드 리서치 코오포레이션 효소 민감성 결합을 갖는 Ｉｎ Ｖｉｖｏ 폴리뉴클레오티드 전달 컨쥬게이트
JP2014531476A (ja) 2011-08-26 2014-11-27 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ（ビニルエステル）ポリマー
PE20142362A1 (es) * 2011-11-18 2015-01-30 Alnylam Pharmaceuticals Inc Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CA2842041A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
BR112017025698A2 (pt) 2015-05-29 2018-08-14 Arrowhead Pharmaceuticals Inc composições e métodos para inibir a expressão do gene de hif2alfa
ES2842300T3 (es) * 2015-07-31 2021-07-13 Alnylam Pharmaceuticals Inc Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
NZ744357A (en) 2016-03-07 2025-09-26 Arrowhead Pharmaceuticals Inc Targeting ligands for therapeutic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141703A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
JP2015522255A (ja) 2012-05-24 2015-08-06 アイシス ファーマシューティカルズ， インコーポレーテッド アポリポタンパク質（ａ）発現を調節するための方法および組成物
WO2014179625A1 (en) 2013-05-01 2014-11-06 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Cardiovascular Translational Research，2015年01月，Vol.8，pp.44-53

Also Published As

Publication number Publication date
US10662427B2 (en) 2020-05-26
SMT202100622T1 (it) 2022-01-10
RS62523B1 (sr) 2021-11-30
WO2017059223A2 (en) 2017-04-06
JP2018529732A (ja) 2018-10-11
CA3000397A1 (en) 2017-04-06
TW202449154A (zh) 2024-12-16
AU2022283623B2 (en) 2025-07-10
SG10202008530TA (en) 2020-10-29
TWI836693B (zh) 2024-03-21
JOP20160211B1 (ar) 2021-08-17
TWI784934B (zh) 2022-12-01
LT3356529T (lt) 2021-12-27
WO2017059223A3 (en) 2017-05-11
MX2018003833A (es) 2018-06-18
US20180195070A1 (en) 2018-07-12
JP2024009262A (ja) 2024-01-19
JP7442574B2 (ja) 2024-03-04
ES2896298T3 (es) 2022-02-24
PT3356529T (pt) 2021-11-04
CO2018003678A2 (es) 2018-11-30
BR112018006489A2 (pt) 2018-10-09
EA201890864A1 (ru) 2018-09-28
DK3356529T3 (da) 2021-11-08
KR20240162596A (ko) 2024-11-15
TW201726918A (zh) 2017-08-01
CN108368506A (zh) 2018-08-03
HRP20211410T1 (hr) 2021-12-24
CR20180231A (es) 2018-05-31
AU2016331084B2 (en) 2022-09-08
IL258333A (en) 2018-05-31
JP2022113835A (ja) 2022-08-04
PH12018500713A1 (en) 2018-10-15
CY1125263T1 (el) 2023-03-24
JOP20210043A1 (ar) 2017-06-16
KR102728481B1 (ko) 2024-11-12
MA43347B1 (fr) 2021-11-30
JP7116212B2 (ja) 2022-08-09
ZA202106265B (en) 2023-08-30
UY36926A (es) 2017-04-28
US20200263179A1 (en) 2020-08-20
IL258333B (en) 2022-03-01
EA038478B1 (ru) 2021-09-03
AU2025242219A1 (en) 2025-10-23
TN2018000094A1 (en) 2019-07-08
US20170096665A1 (en) 2017-04-06
HK1259063A1 (en) 2019-11-22
UA121998C2 (uk) 2020-08-25
EP3356529A2 (en) 2018-08-08
IL300438A (en) 2023-04-01
IL290566A (en) 2022-04-01
HUE055942T2 (hu) 2022-01-28
IL290566B1 (en) 2023-03-01
MY195796A (en) 2023-02-21
CL2018000803A1 (es) 2018-08-31
JP2021087459A (ja) 2021-06-10
EP3356529B1 (en) 2021-08-25
NZ741086A (en) 2023-11-24
US20250115907A1 (en) 2025-04-10
TW202332769A (zh) 2023-08-16
IL290566B2 (en) 2023-07-01
AU2022283623A1 (en) 2023-02-02
MA43347A (fr) 2018-08-08
KR20180052703A (ko) 2018-05-18
AU2016331084A1 (en) 2018-04-19
EP4029941A1 (en) 2022-07-20
US9932586B2 (en) 2018-04-03
PL3356529T3 (pl) 2021-12-20
PE20181139A1 (es) 2018-07-17
MX2022013010A (es) 2022-11-09
SI3356529T1 (sl) 2022-01-31
NZ780687A (en) 2025-06-27
WO2017059223A9 (en) 2017-08-17
EP3356529A4 (en) 2019-09-04
TWI880645B (zh) 2025-04-11

Similar Documents

Publication Publication Date Title
JP7116212B2 (ja) Ｌｐａの遺伝子発現の阻害のための組成物及び方法
TWI811238B (zh) 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物
CN108064313B (zh) 用于抑制因子xii的基因表达的组合物和方法
JP2020505415A (ja) 第ｘｉｉ因子遺伝子発現を阻害するための組成物および方法
JP2024086876A (ja) アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
JP2025186315A (ja) １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
EA048832B1 (ru) Композиции и способы для ингибирования генной экспрессии лпа
HK1259063B (en) Compositions and methods for inhibiting gene expression of lpa

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211208

R150 Certificate of patent or registration of utility model

Ref document number: 6991966

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250